VitaNova Life Sciences Corporation Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Excluding Exchange Rate Effect
VitaNova Life Sciences Corporation (VNOV) reported Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Excluding Exchange Rate Effect of $6.96 thousand for the 3-month period ending 2026-07-31, per its 10-Q filed 2026-09-14.
Financial Statements › Cash Flow
us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect · last filed 2026-09-14
- VitaNova Life Sciences Corporation cash, cash equivalents, restricted cash and restricted cash equivalents, period increase (decrease), excluding exchange rate effect for the quarter ending 2026-07-31 was $6.96K, a 97.36% decline year-over-year.
- VitaNova Life Sciences Corporation cash, cash equivalents, restricted cash and restricted cash equivalents, period increase (decrease), excluding exchange rate effect for the quarter ending 2025-07-31 was $263.81K.
- VitaNova Life Sciences Corporation cash, cash equivalents, restricted cash and restricted cash equivalents, period increase (decrease), excluding exchange rate effect for the quarter ending 2024-07-31 was -$451.40K.
- VitaNova Life Sciences Corporation cash, cash equivalents, restricted cash and restricted cash equivalents, period increase (decrease), excluding exchange rate effect for the quarter ending 2023-07-31 was -$8.73K, a 228.71% decline year-over-year.
- VitaNova Life Sciences Corporation cash, cash equivalents, restricted cash and restricted cash equivalents, period increase (decrease), excluding exchange rate effect for fiscal 2026 was $814.41K, a 329.15% increase from fiscal 2025.
- VitaNova Life Sciences Corporation cash, cash equivalents, restricted cash and restricted cash equivalents, period increase (decrease), excluding exchange rate effect for fiscal 2025 was $189.77K, a 67.52% decline from fiscal 2024.
- VitaNova Life Sciences Corporation cash, cash equivalents, restricted cash and restricted cash equivalents, period increase (decrease), excluding exchange rate effect for fiscal 2024 was $584.31K.
- VitaNova Life Sciences Corporation cash, cash equivalents, restricted cash and restricted cash equivalents, period increase (decrease), excluding exchange rate effect for fiscal 2023 was -$14.38K, a 162.22% decline from fiscal 2022.
| Period end | Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Excluding Exchange Rate Effect 3 month | Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Excluding Exchange Rate Effect 3 month as first filed | Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Excluding Exchange Rate Effect 6 month | Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Excluding Exchange Rate Effect 9 month | Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Excluding Exchange Rate Effect 12 month |
|---|---|---|---|---|---|
| 2026-07-31 | $6.96K 10-Q · filed 2026-09-14 | ||||
| 2026-04-30 | $814.41K 10-K · filed 2026-07-29 | ||||
| 2026-01-31 | $386.09K 10-Q · filed 2026-03-16 | ||||
| 2025-10-31 | $476.47K 10-Q · filed 2025-12-15 | ||||
| 2025-07-31 | $263.81K 10-Q · filed 2026-09-14 | $263.81K 10-Q · filed 2025-09-12 | |||
| 2025-04-30 | $189.77K 10-K · filed 2026-07-29 | ||||
| 2025-01-31 | -$187.86K 10-Q · filed 2026-03-16 | ||||
| 2024-10-31 | -$370.24K 10-Q · filed 2025-12-15 | ||||
| 2024-07-31 | -$451.40K 10-Q · filed 2025-09-12 | ||||
| 2024-04-30 | $584.31K 10-K · filed 2025-07-24 | ||||
| 2024-01-31 | $799.63K 10-Q · filed 2025-03-17 | ||||
| 2023-10-31 | -$8.73K 10-Q · filed 2024-12-13 | ||||
| 2023-07-31 | -$8.73K 10-Q · filed 2024-09-10 | ||||
| 2023-04-30 | -$14.38K 10-K · filed 2024-07-29 | ||||
| 2023-01-31 | -$12.09K 10-Q · filed 2024-03-11 | ||||
| 2022-10-31 | $12.09K 10-Q · filed 2023-12-15 | ||||
| 2022-07-31 | $6.78K 10-Q · filed 2023-09-14 | ||||
| 2022-04-30 | $23.10K 10-K · filed 2023-05-15 | ||||
| 2022-01-31 | $36.94K 10-Q · filed 2023-02-16 | ||||
| 2021-10-31 | $31.69K 10-Q · filed 2022-11-14 | ||||
| 2021-07-31 | $0.00 10-Q · filed 2022-09-01 | ||||
| 2021-01-31 | $0.00 10-Q · filed 2022-02-17 | ||||
| 2020-10-31 | $0.00 10-Q · filed 2021-11-10 | ||||
| 2020-07-31 | $0.00 10-Q · filed 2021-08-20 |